What To Read - November Update from Biopharma PEG

Hi <<First Name>>,
Here, you'll find the most useful content that we've recently published on our blog.

Featured Video

What are Antibody Drug Conjugates (ADCs)? What are the components of ADCs? HOW do ADCs work as cancer therapy? Find out in this video.

Watch the video>>

In the News This Month

Long Acting PEGylated Interferon: Application of PEG

Find out here the types of Interferons (IFNs) and their major clinical uses. Moreover, find more details of long-acting PEGylated IFNs.... More>>

FDA Approves Besremi (ropeginterferon alfa-2b-njft) for Treating Polycythemia Vera

On 12 November 2021, the US FDA has approved Besremi, developed by Pharma Essentia, for the treatment of polycythemia vera.... More>>

Peptide Drug Conjugates (PDCs): New Generation of Targeted Cancer Treatment

PDCs (Peptide Drug Conjugates) is a new type of conjugated drug. Find out the advantages of PDCs, clinical application of PDCs in cancer and future directions of PDCs... More>>

Existing Strategies For Designing Long-Acting Protein and Peptide Drugs

The clinical potential of peptide and protein drugs is often hampered by their inherent short serum half-life. A number of long-acting technologies can extend the their half-life... More>>

About Biopharma PEG

Biopharma PEG is a leading supplier of PEG linkers, including high purity monodisperse PEG and Polymer PEG to empower our customer's advanced research worldwide. These compounds feature great aqueous solubility, wide range of polymer length/weight, and a broad selection of all the popular PEGylation functional groups. Please visit our product page for all our in-stock PEG Linkers.

Learn More>>